News

The sBLA was submitted by Genmab’s licensing partner, Janssen Biotech, Inc., in November 2017. Priority Review is an FDA designation for drugs that treat a serious condition and

SymBio holds approval for TREAKISYM injectables which are already used for the treatment of three indications of malignant lymphoma (first-line and relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma and mantle

Lynparza has been approved as a maintenance treatment for patients in whom ovarian cancer had relapsed, and are sensitive to platinum chemotherapy. The approval for the treatment is

Final patient data from the trial are being collated and entered into the database, checked and analysed. This process is ongoing and top line results remain on track

The investment will increase the good manufacturing practice (GMP) footprint at the campus by more than thrice. Slated to be operationally ready by the start of next year,

Freeline’s technology uses engineered adeno-associated virus (AAV) vectors for the treatment of bleeding and other debilitating disorders. Freeline will deploy their proprietary manufacturing platform for production of clinical

Argentum Pharmaceuticals brought the challenge to the patent, in a proceeding called inter partes review. Argentum disputed all claims of Janssen's U.S. Patent No. 8,822,438, which will expire on

The new agreement focuses on the synthesis and delivery of custom libraries to AstraZeneca as well as the transfer of the DEX platform, allowing for in-house screening of

The round was co-led by new investor Horizons Ventures of Hong Kong and existing investor The Column Group, and joined by private investors including Jerome Dahan. Patrick Zhang